ClearPoint Neuro Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Stifel Reiterated a Buy Rating on the Stock and Raised Its Price Target From $8 to $9
ClearPoint Neuro公佈的第四季度財務業績好於預期並重申了24財年的收入指導，此後，該公司股價走高。此外，Stifel重申了對該股的買入評級，並將其目標股價從8美元上調至9美元